Free Trial
OTCMKTS:IPHYF

Innate Pharma (IPHYF) Stock Price, News & Analysis

Innate Pharma logo
$2.90 0.00 (0.00%)
As of 03/28/2025

About Innate Pharma Stock (OTCMKTS:IPHYF)

Key Stats

Today's Range
$2.90
$2.90
50-Day Range
$2.90
$2.90
52-Week Range
$1.28
$2.90
Volume
N/A
Average Volume
N/A
Market Capitalization
$232.61 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.

Remove Ads

Innate Pharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
4th Percentile Overall Score

IPHYF MarketRank™: 

Innate Pharma scored higher than 4% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Innate Pharma.

  • Price to Book Value per Share Ratio

    Innate Pharma has a P/B Ratio of 4.14. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    0.00% of the float of Innate Pharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Innate Pharma has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

  • Dividend Yield

    Innate Pharma does not currently pay a dividend.

  • Dividend Growth

    Innate Pharma does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.00% of the float of Innate Pharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Innate Pharma has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

  • News Coverage This Week

    MarketBeat has tracked 1 news article for Innate Pharma this week, compared to 0 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Innate Pharma insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    31.89% of the stock of Innate Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Read more about Innate Pharma's insider trading history.
Receive IPHYF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Innate Pharma and its competitors with MarketBeat's FREE daily newsletter.

IPHYF Stock News Headlines

7 Stocks Set to Win Big Under Trump’s America First Agenda 🚀
The Trump economy is back in full force, and it’s creating huge opportunities for investors. With Trump pushing for lower taxes, fewer regulations, tariffs on foreign competitors, and domestic manufacturing dominance, some stocks are set to skyrocket in value—while others will be left behind. That’s why we put together this free report revealing the 7 MAGA stocks poised to thrive in 2025.
3 Promising Penny Stocks With Market Caps Under US$500M
Evercore ISI Sticks to Its Buy Rating for Innate Pharma (IPHA)
See More Headlines

IPHYF Stock Analysis - Frequently Asked Questions

Innate Pharma's stock was trading at $2.90 at the beginning of 2025. Since then, IPHYF shares have increased by 0.0% and is now trading at $2.90.
View the best growth stocks for 2025 here
.

Shares of IPHYF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Today
3/31/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
OTCMKTS:IPHYF
Previous Symbol
NASDAQ:IPHYF
Employees
179
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$66.71 million
Price / Cash Flow
N/A
Book Value
$0.70 per share
Price / Book
4.14

Miscellaneous

Free Float
57,097,000
Market Cap
$232.61 million
Optionable
Not Optionable
Beta
1.07
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This page (OTCMKTS:IPHYF) was last updated on 3/31/2025 by MarketBeat.com Staff
From Our Partners